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Rheumatology International (2018) 38:2225–2231  
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The article “On-drug and drug-free remission by base-
line symptom duration: abatacept with methotrexate in 
patients with early rheumatoid arthritis”, written by Viv-
ian P.Bykerk, was originally published Online First with-
out open access. After publication in volume [38], issue 
[12], page [2225–2231] the author decided to opt for Open 
Choice and to make the article an open access publication. 
Therefore, the copyright of the article has been changed to 
© The Author(s) 2018 and the article is forthwith distributed 
under the terms of the Creative Commons Attribution 4.0 
International License (http://creat iveco mmons .org/licen ses/
by/4.0/), which permits use, duplication, adaptation, distri-
bution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons license 
and indicate if changes were made.
The original article has been corrected.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
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The original article can be found online at https ://doi.org/10.1007/
s0029 6-018-4173-3.
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